Proactive Investors - Run By Investors For Investors

CytoDyn files for Orphan Drug designation to treat triple-negative breast cancer

CytoDyn Inc (OTCQB:CYDY) CEO Dr. Nader Pourhassan and Chief Medical Officer Dr. Richard Pestell tell Proactive Investors the biotech was able to reduce the incidence of human breast cancer metastasis in a mouse model for cancer with flagship drug leronlimab by more than 98%.

The biotech has filed for Orphan Drug designation to treat triple-negative breast cancer. It also announced plans earlier this week to expand pre-clinical animal studies into eight cancer indications.

 
View full CYDY profile View Profile

CytoDyn Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use